loratidine

# loratidine ## Overview - **Classification**: Second-generation antihistamine, non-sedating. - **Mechanism**: Selective peripheral H1-receptor antagonist. Blocks histamine release, preventing allergic symptoms. ## Primary Indications 1. **Seasonal Allergic Rhinitis (SAR)** - Relief of sneezing, rhinorrhea, pruritus, ocular pruritus. 2. **Perennial Allergic Rhinitis (PAR)** - Relief of symptoms similar to SAR. 3. **Chronic Idiopathic Urticaria (CIU)** - Relief of pruritus and reduction of hives. ## Adult Dosing ### Standard Dosing **Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria** - **Dose**: **10 mg** - **Frequency**: Once daily - **Route**: Oral - **Duration**: As needed for symptom control. ### Dose Adjustments - **Renal Impairment**: CrCl < 30 mL/min: **10 mg** every other day. - **Hepatic Impairment**: Initial dose **10 mg** every other day. - **Elderly Patients**: No specific adjustment for age; consider renal/hepatic status. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: Not recommended. - **Frequency**: Not recommended. - **Special Notes**: Safety and efficacy not established. Avoid use. ### Infants (1-12 months) - **Dose**: Not recommended. - **Frequency**: Not recommended. - **Special Notes**: Safety and efficacy not established. Avoid use. ### Children (1-2 years) - **Primary Indication (SAR, PAR, CIU)** - **Dose**: **2.5 mg** - **Frequency**: Once daily - **Maximum**: **2.5 mg/day** - **Formulation**: Oral solution (**1 mg/mL**) often preferred. ### Children (2-5 years) - **Primary Indication (SAR, PAR, CIU)** - **Dose**: **5 mg** - **Frequency**: Once daily - **Maximum**: **5 mg/day** - **Formulation**: Oral solution (**1 mg/mL**) or chewable tablet (5 mg). ### Children (6-12 years) - **Primary Indication (SAR, PAR, CIU)** - **Dose**: **10 mg** - **Frequency**: Once daily - **Maximum**: **10 mg/day** (equivalent to adult dose). - **Formulation**: Tablet (10 mg), chewable tablet (5 mg), oral solution (1 mg/mL). ### Adolescents (13-18 years) - **Dose**: Treat as adult dosing, **10 mg** - **Frequency**: Once daily - **Maximum**: **10 mg/day** ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to loratadine or its components. - **Absolute**: Not for use in neonates and infants <1 year. ### Common Adverse Effects - **Very Common (>10%)**: Headache, somnolence (less common than 1st gen). - **Common (1-10%)**: Fatigue, dry mouth, pharyngitis, insomnia, nervousness. - **Serious but Rare**: Anaphylaxis, angioedema, hepatotoxicity (very rare). ### Key Drug Interactions - **CYP3A4/CYP2D6 Inhibitors (e.g., ketoconazole, erythromycin, cimetidine)**: May increase loratadine levels. Clinical significance usually minimal. - **Alcohol**: Does not potentiate alcohol effects, unlike first-generation antihistamines. ## Monitoring & Follow-up - **Before Treatment**: No routine baseline laboratory tests required. - **During Treatment**: Monitor for symptom improvement and adverse effects (e.g., drowsiness, dry mouth). - **Clinical Signs**: Assess reduction in allergy symptoms (sneezing, itching, hives). ## Clinical Pearls - 💡 **Timing**: Can be taken with or without food. Taking in the morning is common for daily allergy control. - 💡 **Formulations**: Available as tablets, orally disintegrating tablets, chewable tablets, and oral solution for flexibility. - 💡 **Sedation**: Generally non-sedating, but mild drowsiness can occur in some individuals. - 💡 **Onset of action**: Effects typically begin within 1-3 hours, peak at 8-12 hours, lasting 24 hours. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.